Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 22 of 26 · 1223 articles
Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor.
New long-term and real-world data about risankizumab and upadacitinib may influence treatment choices and expectations about symptom relief, steroid-sparing effects, treatment persistence, and hospitalization risk for...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
Mucosal healing is a treatment goal that aims to stop internal intestinal inflammation, not just symptoms. Achieving mucosal healing is linked with fewer hospitalizations, less need for surgery, and lower rates of...
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from jnj.com.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.
A subcutaneous induction option for SKYRIZI could let people with Crohn’s start and continue treatment with injections instead of beginning with an IV infusion, which may affect convenience, time in clinic, and infusion...
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
Cure8 found this source from journals.sagepub.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Corticosteroids. Open the original article for the full...
Cure8 could only read part of this source from gurufocus.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications.
Treg cell therapy aims to reduce harmful immune activity that drives Crohn's disease. If developed successfully, it could become a targeted cell-based treatment option for patients who don't respond to current therapies.
Cure8 could only read part of this source from webmd.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications.
Fatigue affects a large majority of pediatric IBD patients and is linked to worse quality of life even when disease is in remission, so it’s a common problem families and clinicians will likely encounter. Understanding...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.
Cure8 found this source from tmcnet.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Stricture. Open the original article for the full details.
An interchangeable FDA approval can increase availability and potentially reduce costs for biologic treatments used in Crohn’s disease and ulcerative colitis. This may affect medication access, pharmacy substitution, and...
Based on the title and source metadata, this appears to be a regulatory update related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from msn.com.
TREMFYA (guselkumab) is an IL-23 inhibitor being studied for ulcerative colitis and Crohn's disease; new trial data could affect future treatment options. For people with IBD, drug-development news may indicate upcoming...
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.
An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...
Based on the title and source metadata, this appears to be a market or business news related to Ulcerative colitis, Crohn's disease, and Guselkumab. The original article is from firstwordpharma.com.
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from gastroendonews.com.
Formulary listings for Yesintek (ustekinumab biosimilar) could make an established IBD treatment more affordable and accessible for people with Crohn’s disease or ulcerative colitis. Wider payer coverage may affect which...
Perianal Crohn’s can cause severe pain, abscesses, and fistulas that affect daily life and sports. This story shows one person’s path through diagnosis, medical treatment, surgery, and peer support, which may resonate...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
This is a patient-friendly summary explaining what Crohn’s disease is, common symptoms, and typical treatment and monitoring approaches. It can help people recognize symptoms and understand basic management options.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from msn.com.
Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
People with Crohn’s disease and their clinicians need ways to predict which medication will work best and to know how different drugs compare. Better predictors and head-to-head trials could reduce trial-and-error...
The video discusses trials testing combinations of existing Crohn’s therapies with different mechanisms to potentially boost treatment effectiveness. If successful, combination approaches could expand options for people...
Cure8 could only read part of this source from ajmc.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Upadacitinib.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.
Cure8 found this source from wam.ae, but the page could not be read reliably yet. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor. Open the original article for the full details.
This article reports on ENTYVIO (vedolizumab), a biologic used in Crohn's disease and ulcerative colitis, highlighting broader availability of a subcutaneous option and ongoing market growth—topics that can affect drug...
If you take biologic therapy for Crohn’s disease or ulcerative colitis, this study suggests brief overlaps when switching drugs may not increase infection risk, which could mean fewer gaps in treatment and less risk of...
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
Cure8 could only read part of this source from ajmc.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Vedolizumab, and Anti Integrin.
This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.
Regulatory approval means ustekinumab (Stelara) can now be prescribed in the EU for some children with moderate‑to‑severe Crohn’s disease who haven’t responded to other treatments. This expands treatment options for...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Upadacitinib. Open the original article for the...
